AMPK activation is sufficient to increase skeletal muscle glucose uptake and glycogen synthesis but is not required for contraction-mediated increases in glucose metabolism.

AMPK Metabolism Pharmacology Skeletal muscle

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 21 09 2021
revised: 13 12 2021
accepted: 10 10 2022
entrez: 28 10 2022
pubmed: 29 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

The AMP-activated protein kinase (AMPK) is a cellular sensor of energetics and when activated in skeletal muscle during contraction can impart changes in skeletal muscle metabolism. Therapeutics that selectively activate AMPK have been developed to lower glucose levels through increased glucose disposal rates as an approach to abrogate the hyperglycemic state of diabetes; however, the metabolic fate of glucose following AMPK activation remains unclear. We have used a combination of

Identifiants

pubmed: 36303906
doi: 10.1016/j.heliyon.2022.e11091
pii: S2405-8440(22)02379-9
pmc: PMC9593205
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e11091

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following conflict of interests: Some of the authors on this manuscript were employees of Pfizer Inc. during the studies reported.

Références

Adv Physiol Educ. 2014 Dec;38(4):308-14
pubmed: 25434013
Nat Rev Endocrinol. 2016 Nov;12(11):633-645
pubmed: 27448057
J Biol Chem. 2004 Jan 9;279(2):1070-9
pubmed: 14573616
Nature. 1957 Jun 15;179(4572):1235-7
pubmed: 13440944
FASEB J. 2014 Jul;28(7):3211-24
pubmed: 24652947
Am J Physiol. 1996 Feb;270(2 Pt 1):E299-304
pubmed: 8779952
J Biol Chem. 1993 Aug 5;268(22):16113-5
pubmed: 8344895
J Biol Chem. 1979 Jan 25;254(2):420-30
pubmed: 762069
Cell Metab. 2014 Dec 2;20(6):939-52
pubmed: 25448702
Science. 2017 Aug 4;357(6350):507-511
pubmed: 28705990
J Clin Invest. 2001 Oct;108(8):1167-74
pubmed: 11602624
Nat Rev Endocrinol. 2017 Mar;13(3):133-148
pubmed: 27739515
Structure. 2014 Aug 5;22(8):1161-1172
pubmed: 25066137
Respir Physiol. 1968 May;4(3):292-300
pubmed: 4300574
J Physiol. 2006 Dec 15;577(Pt 3):1021-32
pubmed: 17038425
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16092-7
pubmed: 21896769
Nat Metab. 2020 Sep;2(9):817-828
pubmed: 32747792
Exp Gerontol. 1998 Jun;33(4):303-18
pubmed: 9639167
Bioinformatics. 2014 May 1;30(9):1333-5
pubmed: 24413674
EBioMedicine. 2018 May;31:122-132
pubmed: 29673898
J Pharmacol Exp Ther. 2017 May;361(2):303-311
pubmed: 28289077
J Gen Physiol. 1963 May;46:929-69
pubmed: 13957780
Cell Metab. 2017 May 2;25(5):1147-1159.e10
pubmed: 28467931
FASEB J. 2018 Apr;32(4):1741-1777
pubmed: 29242278
Mol Cell. 2001 May;7(5):1085-94
pubmed: 11389854
Diabetes. 2019 Jul;68(7):1427-1440
pubmed: 31010958

Auteurs

Ryan M Esquejo (RM)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Bina Albuquerque (B)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Anna Sher (A)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Matthew Blatnik (M)

Early Clinical Development, Pfizer Inc., Groton, CT 06340, United States.

Kyle Wald (K)

Early Clinical Development, Pfizer Inc., Groton, CT 06340, United States.

Matthew Peloquin (M)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Jake Delmore (J)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Erick Kindt (E)

Worldwide Research, Development, and Medical Affairs, Pfizer Inc., La Jolla, CA 92037, United States.

Wenlin Li (W)

Worldwide Research, Development, and Medical Affairs, Pfizer Inc., La Jolla, CA 92037, United States.

Jamey D Young (JD)

Department of Chemical & Biomolecular Engineering, Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN 37235-1604, United States.

Kim Cameron (K)

Worldwide Research, Development, and Medical Affairs, Pfizer Inc., Cambridge, MA 02139, United States.

Russell A Miller (RA)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, United States.

Classifications MeSH